We are developing breast cancer therapeutics based on 24 yrs of research experience specifically in this field. Through our research, we identified an enzyme that is fundamental for the growth of breast cancer, the enzyme is called RSK (ribosomal S6 kinase). Our company has developed proprietary RSK inhibitors that kill breast cancer cells. However they are not harmful to normal cells providing a revolutionary way of treating the disease.